GeneDx Holdings (WGS) Revenue (2020 - 2026)

GeneDx Holdings (WGS) has reported Revenue for 7 consecutive years, with $114.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Revenue rose 11.44% year-over-year to $114.4 million in Q2 2026; TTM through Jun 2026 was $454.4 million, a 25.42% increase from a year earlier, with the FY2025 full-year figure at $427.5 million, up 39.97% from the prior year.
• Revenue was $114.4 million for Q2 2026 at GeneDx Holdings, up from $102.3 million in the prior quarter.
• Over five years, Revenue peaked at $121.0 million in Q4 2025 and troughed at $36.2 million in Q2 2022.
• A 5-year average of $77.1 million and a median of $73.7 million in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue surged 92.77% in 2022 and slumped 35.96% in 2023, its largest moves.
• Over 5 years, Revenue stood at $61.4 million in 2022, then dropped by 6.41% to $57.4 million in 2023, then jumped by 66.57% to $95.6 million in 2024, then gained by 26.5% to $121.0 million in 2025, then fell by 5.41% to $114.4 million in 2026.
• The last three Revenue figures came in at $114.4 million (Q2 2026), $102.3 million (Q1 2026), and $121.0 million (Q4 2025), per Business Quant data.